Who
Raul R. Rodriguez
CEO, President
Company insider
Files Form 4 as: CEO, President, Rigel Pharmaceuticals.
In numbers
- Trades disclosed
- 82
- Buys
- 2
- Sells
- 5
- Bought
- $990K
- Sold
- $296K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 25 Jan 2006
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $115K2,424 at $47.50 | filing |
| 1 Sep 2026filed 3 Sep 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $115K2,424 at $47.50 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —31,700 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —31,700 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $72K2,424 at $29.86 | filing |
| 1 Jun 2026filed 3 Jun 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $72K2,424 at $29.86 | filing |
| 17 Feb 2026filed 19 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —53,915 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —53,915 at $0.00 | filing |
| 10 Feb 2026filed 12 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $263K7,607 at $34.62 | filing |
| 10 Feb 2026filed 12 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $263K7,607 at $34.62 | filing |
| 2 Feb 2026filed 4 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $508K14,110 at $36.01 | filing |
| 2 Feb 2026filed 4 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $508K14,110 at $36.01 | filing |
| 26 Jan 2026filed 4 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $1.1M40,000 at $27.40 | filing |
| 26 Jan 2026filed 4 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $1.3M35,211 at $37.00 | filing |
| 26 Jan 2026filed 4 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $1.1M40,000 at $27.40 | filing |
| 26 Jan 2026filed 4 Feb 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 26 Jan 2026filed 4 Feb 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 26 Jan 2026filed 4 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $1.3M35,424 at $37.00 | filing |
| 26 Jan 2026filed 4 Feb 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 26 Jan 2026filed 4 Feb 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.